Transactions
24
Insider / Attovia Therapeutics, Inc.
Sanofi
Insider at Attovia Therapeutics, Inc.
- Company
- Attovia Therapeutics, Inc.
- First filing on record
- July 23, 2019
- Latest trade on record
- August 10, 2026
- SEC filings
- EDGAR ↗
Sanofi, Insider at Attovia Therapeutics, Inc., has disclosed 24 transactions in LTGO, ATTO, TBIO and 4 more since July 23, 2019: 6 purchases (6 open-market buys) and 5 sales, worth about $14.56B at the reported prices. The latest was filed August 12, 2026, 2 days after the trade.
Open-market buys
6
Sales
5
Avg. disclosure lag
1.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Sanofi made 1 purchase worth $5.1M and no sales, plus 6 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Sanofi has traded 6 stocks on record; the largest by dollars is REGN.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 10 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| C | Conversion of a derivative | 13 | 26,267,539 | — |
| P | Open-market purchase | 6 | 72,525,264 | $2.74B |
| S | Open-market sale | 5 | 23,243,503 | $11.82B |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 7 | 1 · $5.1M | 0 |
| 2021 | 6 | 3 · $2.74B | 0 |
| 2020 | 7 | 1 · $1.3M | 4 · $11.77B |
| 2019 | 4 | 1 · $1.5M | 1 · $48.6M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| LTGO | Exchange C | August 10, 2026 | August 12, 2026 | 2d | 177,978 | — | — | indirectderivative | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 12, 2026 | 2d | 494,800 | — | — | indirectderivative | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 12, 2026 | 2d | 177,978 | — | — | indirect | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 12, 2026 | 2d | 494,800 | — | — | indirect | Form 4 ↗ | |
| ATTO | Exchange C | August 6, 2026 | August 7, 2026 | 1d | 782,855 | — | — | indirectderivative | Form 4 ↗ | |
| ATTO | Buy P | August 6, 2026 | August 7, 2026 | 1d | 300,000 | $17 | $5.1M | indirect | Form 4 ↗ | |
| ATTO | Exchange C | August 6, 2026 | August 7, 2026 | 1d | 782,855 | — | — | indirect | Form 4 ↗ | |
| TBIO | Buy P | September 14, 2021 | September 14, 2021 | 0d | 20,515,985 | $38 | $779.6M | Form 4 ↗ | ||
| TBIO | Buy P | September 14, 2021 | September 14, 2021 | 0d | 51,467,612 | $38 | $1.96B | Form 4 ↗ | ||
| ICVX | Exchange C | August 2, 2021 | August 2, 2021 | 0d | 354,393 | — | — | indirectderivative | Form 4 ↗ | |
| ICVX | Exchange C | August 2, 2021 | August 2, 2021 | 0d | 12,480,498 | — | — | indirectderivative | Form 4 ↗ | |
| ICVX | Buy P | August 2, 2021 | August 2, 2021 | 0d | 66,667 | $15 | $1.0M | indirect | Form 4 ↗ | |
| ICVX | Exchange C | August 2, 2021 | August 2, 2021 | 0d | 3,088,502 | — | — | indirect | Form 4 ↗ | |
| INZY | Exchange C | July 28, 2020 | July 29, 2020 | 1d | 3,279,720 | — | — | indirectderivative | Form 4 ↗ | |
| INZY | Buy P | July 28, 2020 | July 29, 2020 | 1d | 81,250 | $16 | $1.3M | indirect | Form 4 ↗ | |
| INZY | Exchange C | July 28, 2020 | July 29, 2020 | 1d | 438,875 | — | — | indirect | Form 4 ↗ | |
| REGN | Sell S | June 9, 2020 | June 11, 2020 | 2d | 120,234 | $597 | $71.8M | indirect | Form 4 ↗ | |
| REGN | Sell S | May 29, 2020 | May 29, 2020 | 0d | 2,399,552 | $510 | $1.22B | indirect | Form 4 ↗ | |
| REGN | Sell S | May 29, 2020 | May 29, 2020 | 0d | 20,421,899 | $510 | $10.41B | Form 4 ↗ | ||
| REGN | Sell S | March 9, 2020 | March 11, 2020 | 2d | 128,914 | $490 | $63.1M | Form 4 ↗ | ||
| REGN | Sell S | September 10, 2019 | September 12, 2019 | 2d | 172,904 | $281 | $48.6M | Form 4 ↗ | ||
| FULC | Exchange C | July 22, 2019 | July 23, 2019 | 1d | 3,250,000 | — | — | indirectderivative | Form 4 ↗ | |
| FULC | Buy P | July 22, 2019 | July 23, 2019 | 1d | 93,750 | $16 | $1.5M | indirect | Form 4 ↗ | |
| FULC | Exchange C | July 22, 2019 | July 23, 2019 | 1d | 464,285 | — | — | indirect | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 12, 2026 | Form 4 | 0001193125-26-345826 | 4 | published | EDGAR ↗ |
| August 7, 2026 | Form 4 | 0001193125-26-340173 | 3 | published | EDGAR ↗ |
| September 14, 2021 | Form 4 | 0000899243-21-035757 | 2 | published | EDGAR ↗ |
| August 2, 2021 | Form 4 | 0000899243-21-031120 | 4 | published | EDGAR ↗ |
| July 29, 2020 | Form 4 | 0000899243-20-020587 | 3 | published | EDGAR ↗ |
| June 11, 2020 | Form 4 | 0001140361-20-013625 | 1 | published | EDGAR ↗ |
| May 29, 2020 | Form 4 | 0001140361-20-012718 | 2 | published | EDGAR ↗ |
| March 11, 2020 | Form 4 | 0001140361-20-005506 | 1 | published | EDGAR ↗ |
| September 12, 2019 | Form 4 | 0001140361-19-016600 | 1 | published | EDGAR ↗ |
| July 23, 2019 | Form 4 | 0000899243-19-020073 | 3 | published | EDGAR ↗ |
Other insiders at Attovia Therapeutics, Inc.
- RYAN ARTHUR F Director 50 rows
- MURPHY ANDREW J EVP Research 38 rows
- GOLDMAN SACHS GROUP INC Insider 29 rows
- WALSH COLIN Director 29 rows
- POON CHRISTINE A Director 28 rows
- Zoghbi Huda Y Director 18 rows
- Pitofsky Jason SVP Controller 17 rows
- Foresite Capital Management V, LLC Insider 15 rows
- Tananbaum James B. Director 15 rows
- SEIDENBERG BETH C Director 14 rows
Everyone on file, with contracts and lobbying under the company's name: Attovia Therapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 10 | 24 | July 23, 2019 | August 12, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.